Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules

[1]  T. Watts,et al.  TNF/TNFR family members in costimulation of T cell responses. , 2005, Annual review of immunology.

[2]  Fumito Ito,et al.  Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines , 2004, Cancer Research.

[3]  K. Okumura,et al.  Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival , 2004, Transplant international : official journal of the European Society for Organ Transplantation.

[4]  Lieping Chen,et al.  Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens , 2004, International journal of cancer.

[5]  J. Bae,et al.  4‐1BB‐dependent inhibition of immunosuppression by activated CD4+CD25+ T cells , 2004, Journal of leukocyte biology.

[6]  S. Quezada,et al.  CD40/CD154 interactions at the interface of tolerance and immunity. , 2004, Annual review of immunology.

[7]  Youjin Lee,et al.  Priming of naive T cells inside tumors leads to eradication of established tumors , 2004, Nature Immunology.

[8]  T. Shiga,et al.  Phase II clinical trial of high-dose recombinant human tumor necrosis factor , 2004, Cancer Chemotherapy and Pharmacology.

[9]  T. Taguchi,et al.  Phase I study of recombinant human tumor necrosis factor , 2004, Cancer Chemotherapy and Pharmacology.

[10]  G. Zhu,et al.  Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. , 2004, Blood.

[11]  D. Pardoll,et al.  Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.

[12]  J. Crawford,et al.  T cells require TRAIL for optimal graft-versus-tumor activity , 2002, Nature Medicine.

[13]  Lieping Chen,et al.  Signaling Through NK Cell-Associated CD137 Promotes Both Helper Function for CD8+ Cytolytic T Cells and Responsiveness to IL-2 But Not Cytolytic Activity1 , 2002, The Journal of Immunology.

[14]  Aaron J. Johnson,et al.  Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy. , 2002, Cancer research.

[15]  J. Alferink,et al.  Targeted Disruption of LIGHT Causes Defects in Costimulatory T Cell Activation and Reveals Cooperation with Lymphotoxin β in Mesenteric Lymph Node Genesis , 2002, The Journal of experimental medicine.

[16]  M. Fiscella,et al.  Cutting Edge: Selective Impairment of CD8+ T Cell Function in Mice Lacking the TNF Superfamily Member LIGHT , 2002, The Journal of Immunology.

[17]  Lieping Chen,et al.  Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells1 , 2002, The Journal of Immunology.

[18]  A. Dahlin,et al.  Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB , 2002, Nature Medicine.

[19]  S. Busfield,et al.  Modulation of LIGHT-HVEM Costimulation Prolongs Cardiac Allograft Survival , 2002, The Journal of experimental medicine.

[20]  K. Takeda,et al.  Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. , 2002, International immunology.

[21]  Aaron J. Johnson,et al.  Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. , 2002, The Journal of clinical investigation.

[22]  M. Smyth,et al.  Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1 , 2002, The Journal of Immunology.

[23]  David Allman,et al.  Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB , 2002, Nature Biotechnology.

[24]  M. Smyth,et al.  Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development , 2002, The Journal of experimental medicine.

[25]  K. Tamada,et al.  The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. , 2001, The Journal of clinical investigation.

[26]  C. Ware,et al.  Constitutive Expression of LIGHT on T Cells Leads to Lymphocyte Activation, Inflammation, and Tissue Destruction1 2 , 2001, The Journal of Immunology.

[27]  B. Hylander,et al.  Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. , 2001, Cancer research.

[28]  D. Olive,et al.  The TNF Superfamily Members LIGHT and CD154 (CD40 Ligand) Costimulate Induction of Dendritic Cell Maturation and Elicit Specific CTL Activity1 , 2001, The Journal of Immunology.

[29]  K. Schulze-Osthoff,et al.  Potential and caveats of TRAIL in cancer therapy. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[30]  Z. Wang,et al.  Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity , 2001, Nature Medicine.

[31]  Y. Sugiyama,et al.  CD40‐CD40 ligand (CD154) engagement is required but not sufficient for modulating MHC class I, ICAM‐1 and Fas expression and proliferation of human non‐small cell lung tumors , 2001, International journal of cancer.

[32]  J. Gribben,et al.  A pilot study of combined immunotherapy with autologous adoptive tumour‐specific T‐cell transfer, vaccination with CD40‐activated malignant B cells and interleukin 2 , 2001, British journal of haematology.

[33]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[34]  M. Smyth,et al.  Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells , 2001, Nature Medicine.

[35]  B. Dörken,et al.  In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity , 2001, Leukemia.

[36]  D. Adams,et al.  CD40 Induces Apoptosis in Carcinoma Cells through Activation of Cytotoxic Ligands of the Tumor Necrosis Factor Superfamily , 2000, Molecular and Cellular Biology.

[37]  S. Nagata,et al.  Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure , 2000, American Journal of Gastroenterology.

[38]  Lieping Chen,et al.  LIGHT, a TNF-Like Molecule, Costimulates T Cell Proliferation and Is Required for Dendritic Cell-Mediated Allogeneic T Cell Response1 , 2000, The Journal of Immunology.

[39]  G. Zhu,et al.  Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway , 2000, Nature Medicine.

[40]  G. Alvord,et al.  Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1 , 2000, The Journal of Immunology.

[41]  E. Bröcker,et al.  Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. , 2000, Cancer research.

[42]  D. Stuart,et al.  Structure of the TRAIL–DR5 complex reveals mechanisms conferring specificity in apoptotic initiation , 1999, Nature Structural Biology.

[43]  A. Eggermont,et al.  Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. , 1999, Melanoma research.

[44]  M. Ultsch,et al.  Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. , 1999, Molecular cell.

[45]  L. Cavacini,et al.  Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  H. Bien,et al.  Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 , 1999, Nature Medicine.

[47]  T. Schumacher,et al.  CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy , 1999, Nature Medicine.

[48]  Peter Scheurich,et al.  Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF‐R1 activation by endogenous membrane‐anchored TNF , 1999, The EMBO journal.

[49]  Jian Ni,et al.  A Newly Identified Member of Tumor Necrosis Factor Receptor Superfamily (TR6) Suppresses LIGHT-mediated Apoptosis* , 1999, The Journal of Biological Chemistry.

[50]  D. Taub,et al.  Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD40 Ligand , 1999 .

[51]  C. Takahashi,et al.  Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. , 1999, Journal of immunology.

[52]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[53]  D. Adams,et al.  CD40 Activation Induces Apoptosis in Cultured Human Hepatocytes via Induction of Cell Surface Fas Ligand Expression and Amplifies Fas-mediated Hepatocyte Death during Allograft Rejection , 1999, The Journal of experimental medicine.

[54]  W. Fanslow,et al.  Incorporation of an Isoleucine Zipper Motif Enhances the Biological Activity of Soluble CD40L (CD154)* , 1999, The Journal of Biological Chemistry.

[55]  Lieping Chen,et al.  NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. , 1998, Cellular immunology.

[56]  K. Irvine,et al.  CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. , 1998, Journal of immunology.

[57]  A. Eggermont,et al.  Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern. , 1998, Cancer research.

[58]  T. Griffith,et al.  Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. , 1998, Journal of immunology.

[59]  P. Young,et al.  Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines. , 1998, Journal of immunology.

[60]  A. Eggermont,et al.  Assessment of the role of neutrophils on the antitumor effect of TNFalpha in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats. , 1998, The Journal of surgical research.

[61]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[62]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[63]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[64]  L. Zitvogel,et al.  Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. , 1998, Cancer gene therapy.

[65]  Lieping Chen,et al.  Amplification of tumor immunity by gene transfer of the co‐stimulatory 4‐1BB ligand: synergy with the CD28 co‐stimulatory pathway , 1998, European journal of immunology.

[66]  C. Ware,et al.  LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. , 1998, Immunity.

[67]  R. Steinman,et al.  TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.

[68]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.

[69]  C. Ambrose,et al.  Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes. , 1997, Journal of immunology.

[70]  R. Gentz,et al.  An antagonist decoy receptor and a death domain-containing receptor for TRAIL. , 1997, Science.

[71]  W I Wood,et al.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. , 1997, Science.

[72]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[73]  A. Aruffo,et al.  4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses , 1997, The Journal of experimental medicine.

[74]  Lieping Chen,et al.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors , 1997, Nature Medicine.

[75]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[76]  P. Schlag,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.

[77]  E. Schattner,et al.  CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells. , 1996, Blood.

[78]  R. Bataille,et al.  CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. , 1996, Cancer research.

[79]  J. Gribben,et al.  Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[80]  J. Falkenburg,et al.  Proliferation and cytogenetic analysis of hairy cell leukemia upon stimulation via the CD40 antigen. , 1994, Blood.

[81]  A. Eggermont,et al.  Harly endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high‐dose tumour necrosis factor alpha (rTNFα) , 1994 .

[82]  D. Longo,et al.  Inhibition of human B-cell lymphoma growth by CD40 stimulation. , 1994, Blood.

[83]  J. Banchereau,et al.  Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells , 1994, The Journal of experimental medicine.

[84]  A. Eggermont,et al.  Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). , 1994, International journal of cancer.

[85]  K. Pollok,et al.  Inducible T cell antigen 4-1BB. Analysis of expression and function. , 1993, Journal of immunology.

[86]  L. Esserman,et al.  Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones. , 1990, Journal of immunology.

[87]  A. Jones,et al.  Tumour necrosis factor: clinical relevance. , 1989, Cancer surveys.

[88]  J. Kovach,et al.  A phase I clinical trial of recombinant human tumor necrosis factor , 1988, Cancer.

[89]  A. Asher,et al.  Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. , 1987, Journal of immunology.

[90]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.